Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Open Access
- 22 February 1996
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 334 (8), 488-493
- https://doi.org/10.1056/nejm199602223340802
Abstract
Skeletal complications are a major clinical manifestation of multiple myeloma. These complications are caused by soluble factors that stimulate osteoclasts to resorb bone. Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bone resorption.Keywords
This publication has 28 references indexed in Scilit:
- Letter to the editorBone, 1995
- A SINGLE-DOSE BIOAVAILABILITY STUDY OF PAMIDRONATE DISODIUM AFTER ORAL ADMINISTRATION AS ENCAPSULATED ENTERIC-COATED PELLETS, ENTERIC-COATED TABLETS, AND A SOLUTION TO PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSISClinical Journal of Sport Medicine, 1994
- Osteonal and hemi‐osteonal remodeling: The spatial and temporal framework for signal traffic in adult human boneJournal of Cellular Biochemistry, 1994
- Osteoclast inhibition for the treatment of bone metastasesCancer Treatment Reviews, 1993
- Treatment of bone metastases from breast cancer and myeloma with pamidronateEuropean Journal of Cancer and Clinical Oncology, 1991
- Mechanisms of osteolytic bone destructionBone, 1991
- Use of pamidronate for multiple myeloma osteolytic lesionsThe Lancet, 1990
- Controversies in the treatment of plasma cell myelomaPublished by Oxford University Press (OUP) ,1985
- Measuring the quality of life of cancer patientsJournal of Chronic Diseases, 1981
- Effects of Dichloromethylene Diphosphonate on Skeletal Mobilization of Calcium in Multiple MyelomaNew England Journal of Medicine, 1980